Crossmark

A novel combined systemic inflammation-based score can predict survival of intermediate-to-advanced hepatocellular carcinoma patients undergoing transarterial chemoembolization

Crossref DOI link: https://doi.org/10.1186/s12885-018-4121-3

Published Online: 2018-02-21

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Liu, Chang

Li, Lei

Lu, Wu-sheng https://orcid.org/0000-0003-0100-3804
Du, Hua

Yan, Lu-nan

Wen, Tian-fu

Wei, Wu-ran

Jiang, Li

Xu, Ming-qing
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (81400636)
More Information

Article History

Received: 26 July 2017

Accepted: 12 February 2018

First Online: 21 February 2018

Ethics approval and consent to participate

: This study was approved by the Institutional Review Board (IRB) of the West China Hospital, Sichuan University. Informed written consent was obtained from all individual participants included in the study. All the methods used in this study were carried out according to the approved guidelines.

: Not applicable.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current

Any future updates will be listed below